Announcement • Dec 13
Abcam Provides Update on AIM Delisting Abcam plc provided a further update with respect to the cancellation of admission of its Ordinary Shares to trading on AIM (the "AIM Delisting"), as originally announced on 17 October 2022. As previously announced, the last day of trading of the Company's Ordinary Shares on AIM will be 13 December 2022 and the proposed AIM Delisting will be effective from 7.00 a.m. (London time) on 14 December 2022. Abcam will retain the listing of its ADSs, each representing one Ordinary Share, on Nasdaq under the ticker symbol ABCM. Following the AIM Delisting, the Company's ADSs will remain listed, and will only be tradeable, on Nasdaq. Announcement • Oct 18
Abcam plc Announces Proposed Cancellation of AIM Shares Abcam plc announced the Company's intention to cancel the admission of its ordinary shares of nominal value 0.02 pence each (the "Ordinary Shares") to trading on AIM (the "AIM Delisting"), subject to shareholder approval, with effect from December 14, 2022. Subject to shareholder approval, the Company's last day of trading on AIM will be December 13, 2022. Abcam will retain the listing on the Nasdaq Global Select Market ("Nasdaq") of American Depositary Shares, each representing one Ordinary Share (the "ADSs"), under ticker symbol "ABCM", and all public trading of securities in the Company will take place on that exchange. Existing holders of ADSs not also holding Ordinary Shares do not need to take any action in relation to the AIM Delisting; and the posting of a circular to Abcam shareholders (the "Circular"), which contains further information on the AIM Delisting and the process to deposit Ordinary Shares for delivery of ADSs and notice of a general meeting to be held on 11 November 2022 at Discovery Drive, Cambridge Biomedical Campus, Cambridge, CB2 0AX, United Kingdom at 2.00 p.m. (London time) (the "General Meeting") at which shareholder approval will be sought, inter alia, for the AIM Delisting. Announcement • Sep 13
Abcam plc Provides Revenue Guidance for the Full Year Ending December 31, 2022 Abcam plc provided revenue guidance for the full year ending December 31, 2022. For the year, the company currently estimate total revenue to increase approximately 20% CER including the impact from the acquisition of BioVision, with organic CER growth of mid-teens. The company expects the contribution from the sale of higher margin in-house products and the full year effect of BioVision to contribute to a continuing increase in adjusted operating margins. Announcement • Sep 12
Abcam plc Appoints Luba Greenwood as Non-Executive Director Abcam plc announced the appointment of Luba Greenwood as a non-executive Director with immediate effect. Luba's experiences focus on business development and strategy. She is a veteran biotech, pharmaceutical, tech, and life sciences investor and company builder. Luba has held a number of senior leadership and board positions in the healthcare industry. Currently, she serves as the managing partner of the Dana Farber Cancer Institute Venture Fund, Binney Street Capital (BSC), which she has built and launched. Luba is also the CEO of Kojin Therapeutics. Her previous experience includes increasing levels of responsibility at Google Life Sciences, Verily and F. Hoffman-La Roche. Luba has extensive board experience, and currently serves on the board of directors of the following private institutions: MassBio, BenchSci, and In8Bio Inc. Following Luba's appointment, the composition of each of the Board Committees is confirmed as follows: Nomination Committee: Peter Allen (Chair), Mara Aspinall, Giles Kerr. Remuneration Committee: Sally W. Crawford (Chair), Mara Aspinall, Peter Allen, Giles Kerr, Mark Capone. Audit and Risk Committee: Giles Kerr (Chair), Mara Aspinall, Sally W. Crawford. Announcement • Jun 23
Abcam plc to Report First Half, 2022 Results on Sep 12, 2022 Abcam plc announced that they will report first half, 2022 results on Sep 12, 2022 Recent Insider Transactions • Apr 09
Key Executive recently bought €80k worth of stock On the 4th of April, Peter Allen bought around 5k shares on-market at roughly €17.14 per share. This was the largest purchase by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months. Announcement • Apr 05
Abcam plc, Annual General Meeting, May 18, 2022 Abcam plc, Annual General Meeting, May 18, 2022, at 12:00 Coordinated Universal Time. Location: Discovery Drive, Cambridge Biomedical Campus Cambridge CB2 0AX Cambridge United Kingdom Agenda: To receive and adopt the reports of the directors and the financial statements for the period ended 31 December 2021, together with the Independent Auditor's Report; to approve the Annual Report on Directors' Remuneration for the period ended 31 December 2021, as set out on pages 93 to 103 of the Annual Report and Accounts; to approve the Remuneration Policy, as set out on pages 104 to 117 of the Annual Report and Accounts; to re-appoint PricewaterhouseCoopers LLP as auditor of the Company to hold office until the conclusion of the next general meeting at which accounts are laid before the Company; to authorise the Audit and Risk Committee to fix the remuneration of the auditor; to re-elect Directors. Reported Earnings • Mar 15
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: UK£0.019 (up from UK£0.009 loss in FY 2020). Revenue: UK£315.4m (up 17% from FY 2020). Net income: UK£4.40m (up UK£6.30m from FY 2020). Profit margin: 1.4% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 19%, compared to a 76% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance. Announcement • Feb 28
Abcam plc to Report 18 Months Period Ending Dec 31, 2021 Results on Mar 14, 2022 Abcam plc announced that they will report 18 months, period ending Dec 31, 2021 results at 8:00 AM, US Eastern Standard Time on Mar 14, 2022 Announcement • Jan 28
Abcam plc Provides Group Revenue Guidance for the Twelve Months Ended 31 December 2021 Abcam plc provided group revenue guidance for the twelve months ended 31 December 2021. For the year, the company Group expects to report total revenues of approximately £315 million, representing growth of over 22% on a constant exchange rate basis and 17% on a reported basis (12 months to 31 December 2020: £269.3 million). This figure includes a contribution of approximately £2.5 million of incremental revenue1 from BioVision following the acquisition's completion on 27 October 2021. Recent Insider Transactions • Sep 26
CEO & Executive Director recently sold €110k worth of stock On the 23rd of September, Alan Hirzel sold around 6k shares on-market at roughly €17.98 per share. This was the largest sale by an insider in the last 3 months. This was Alan's only on-market trade for the last 12 months. Reported Earnings • Sep 15
Full year 2021 earnings released: EPS UK£0.073 (vs UK£0.06 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: UK£297.7m (up 14% from FY 2020). Net income: UK£16.2m (up 30% from FY 2020). Profit margin: 5.4% (up from 4.8% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance. Announcement • Sep 15
Abcam plc Provides Revenue Guidance for the Six-Months to 31 December 2021 and Year Ending December 31, 2024 Abcam plc provided revenue guidance for the six-months to 31 December 2021 and year ending December 31, 2024. For the six months to December 31, 2021, the company expects revenue growth to be approximately 6%.
For the year ending December 31, 2024, the company expects revenue to be £425 – 500 million. Announcement • Aug 04
Abcam plc (AIM:ABC) entered into a definitive agreement to acquire BioVision, Inc. from Boai NKY Medical Holdings Ltd. (SZSE:300109) for approximately $340 million. Abcam plc (AIM:ABC) entered into a definitive agreement to acquire BioVision, Inc. from Boai NKY Medical Holdings Ltd. (SZSE:300109) for approximately $340 million on August 2, 2021. The consideration of $340 million will be paid on a cash free/debt free basis. Acquisition to be funded from existing cash resources and a partial drawdown of Abcam's Revolving Credit Facility. Acquisition agreement provides for the payment of a reciprocal termination fee of approximately 3% of the purchase price, in the event the Acquisition is terminated in certain specified circumstances. As of December 30, 2020, BioVision generated revenues of $33.8 million, operating profit of $12.6 million, and had Net assets of $21.9 million. The acquisition is expected to be accretive to adjusted earnings per share (EPS) from the first full year of ownership. The acquisition is subject to applicable regulatory clearance and will be subject to review and approval of the Shenzhen Stock Exchange and by a vote of NKY's shareholders. If approved, the acquisition is expected to close before the end of 2021 calendar year. Lazard is acting as financial adviser and Latham & Watkins LLP is acting as legal advisor to Abcam in relation to this transaction. Garry Levin, Freddie Barnfield, and Duncan Monteith of Numis acted as nominated advisors and joint corporate brokers to Abcam. Director Overboarding • Aug 04
Director Mara Aspinall has joined 5th company board Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Aug 04
Director Mara Aspinall has joined 5th company board Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Aug 04
Director Mara Aspinall has joined 5th company board Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Aug 04
Director Mara Aspinall has joined 5th company board Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Aug 04
Director Mara Aspinall has joined 5th company board Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Director Overboarding • Aug 04
Director Mara Aspinall has joined 5th company board Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations. Executive Departure • May 27
Senior Independent Director has left the company On the 19th of May, Louise A. V. Patten's tenure as Senior Independent Director ended after 6.5 years in the role. As of March 2021, Louise A. V. personally held 54.84k shares (€891k worth at the time). Louise A. V. is the only executive to leave the company over the last 12 months. Reported Earnings • Mar 10
First half 2021 earnings released: EPS UK£0.053 (vs UK£0.13 in 1H 2020) The company reported a soft first half result with weaker earnings and profit margins, although revenues improved. First half 2021 results: Revenue: UK£147.5m (up 6.7% from 1H 2020). Net income: UK£11.7m (down 55% from 1H 2020). Profit margin: 7.9% (down from 19% in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Analyst Estimate Surprise Post Earnings • Mar 09
Revenue beats expectations Revenue exceeded analyst estimates by 1.3%. Over the next year, revenue is forecast to grow 18%, compared to a 57% growth forecast for the Biotechs industry in Germany. Is New 90 Day High Low • Feb 13
New 90-day high: €19.25 The company is up 25% from its price of €15.36 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.75 per share. Announcement • Feb 10
Abingdon Health Signs Collaboration and Co-Marketing Agreement with Abcam Abingdon Health Plc has signed a collaboration and co-marketing agreement with Abcam plc. The Parties intend to establish a collaborative strategic relationship to enable them to identify and maximise opportunities for the provision of each Party’s respective products and services, including the wider Abcam reagent portfolio and Abingdon Health’s rapid test contract development and manufacturing services. Under the terms of the agreement, Abcam will be the preferred supplier to Abingdon of gold nanoparticles and custom conjugation reagents and services, for the Company’s lateral flow assays. Custom conjugation reagents will include a combination of an affinity binding reagent such as an antibody, and signal reagents such as the colloidal gold which provides the colour output in a lateral flow assay. Securing a reliable source for custom conjugation reagents ensures reliable supply chains of critical reagents for customers of Abingdon by providing access to the reagents, colloidal gold and specialist conjugation services of Abcam. Announcement • Jan 29
Abcam plc Appoints Non-Executive Directors Abcam plc announced the appointments of Bessie Lee and Mark Capone as non-executive Directors with immediate effect. Based in China, Bessie Lee is the Chief Executive Officer of Withinlink. Based in the US, Mark Capone is an accomplished life sciences executive with more than 35 years’ experience. He spent over 17 years with Myriad Genetics, latterly as Chief Executive Officer and President, over which time he grew the company into a leading global precision medicine company. Is New 90 Day High Low • Jan 13
New 90-day high: €17.98 The company is up 29% from its price of €13.91 on 15 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.22 per share. Announcement • Dec 23
Abcam plc to Report Q2, 2021 Results on Mar 08, 2021 Abcam plc announced that they will report Q2, 2021 results on Mar 08, 2021 Announcement • Nov 04
Abcam plc, Annual General Meeting, Dec 04, 2020 Abcam plc, Annual General Meeting, Dec 04, 2020, at 12:00 Coordinated Universal Time. Location: Discovery Drive, Cambridge Biomedical Campus Cambridge United Kingdom Agenda: To consider and adopt the reports of the directors and the financial statements for the year ended 30 June 2020, together with the independent auditor’s report; to consider and approve the Annual report on directors’ remuneration for the year ended 30 June 2020, as set out on pages 84 to 93 of the annual report and accounts.; to consider re-appoint PricewaterhouseCoopers LLP as auditor of the company to hold office until the conclusion of the next general meeting at which accounts are laid before the company; to consider and authorise the Audit and Risk Committee to fix the remuneration of the auditor; and to consider election of director. Is New 90 Day High Low • Oct 22
New 90-day high: €15.13 The company is up 5.0% from its price of €14.42 on 24 July 2020. The German market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €5.69 per share. Reported Earnings • Oct 04
Full year earnings released - EPS €0.06 Over the last 12 months the company has reported total profits of UK£12.5m, down 72% from the prior year. Total revenue was UK£260.0m over the last 12 months, largely unchanged from the prior year. Profit margins were 4.8%, which is lower than the 17% margin from last year. The decrease in margin was driven by higher expenses. Recent Insider Transactions • Sep 25
Non-Executive Chairman recently bought €49k worth of stock On the 17th of September, Peter Allen bought around 4k shares on-market at roughly €13.73 per share. This was the largest purchase by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months. Announcement • Jul 20
Abcam plc to Report Fiscal Year 2020 Results on Sep 14, 2020 Abcam plc announced that they will report fiscal year 2020 results on Sep 14, 2020